Serving the Society Since 1986
Advanced Search
Volume 41 Issue 1
February 2026
    Citation: Shiqi He, Dongying Fan, Yuqing Guo, Yuheng Guan, Ziyang Sheng, Na Gao, Jing An. Current status of dengue fever epidemics and vaccine development .VIROLOGICA SINICA, 2026, 41(1) : 1-9.  http://dx.doi.org/10.1016/j.virs.2026.01.001
    shu

    Current status of dengue fever epidemics and vaccine development

    • Department of Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China

    • Corresponding author: Ziyang Sheng, shengzy@ccmu.edu.cn
      Na Gao, gao_na@ccmu.edu.cn
    • Received Date: 29 May 2025
      Accepted Date: 16 January 2026
      Available online: 21 January 2026

      Fund Project: the National Natural Science Foundation of Beijing (7232002) to N.G.This work was supported by grants from the National Natural Science Foundation of China (NSFC) (32370163) and the Beijing Municipal Natural Science Foundation-Joint Fund for Clinical Medicine Innovation of the Capital (L2510023) to Z.Y.S.

    • Dengue fever, an acute mosquito-borne infectious disease caused by dengue virus (DENV), is primarily endemic in tropical and subtropical regions. In recent years, the global incidence of dengue has increased dramatically. Since 2023, widespread outbreaks have been reported across numerous countries in the Americas, Asia and Africa. According to the World Health Organization, more than 5 million dengue cases were reported globally in 2023, while the number surged to over 14 million cases with more than 10,000 deaths in 2024—marking the highest global burden ever recorded. A similar upward trend has been observed in China, which experienced its largest dengue outbreak in a decade in 2024, with Guangdong Province accounting for the majority of domestically reported cases. These epidemiological patterns highlight the rapid expansion of dengue transmission, driven by climate change, accelerated urbanization and increased human mobility. In this context, vaccine development has become a public health priority. To date, two vaccines—Dengvaxia and Qdenga—have been licensed for clinical use. Six other vaccine candidates are currently in clinical trials, among which the tetravalent live-attenuated vaccines TV003/TV005 are considered the most promising. Despite considerable advances in dengue vaccine research, significant challenges remain, including the need to elicit balanced immune responses against the four serotypes and to reduce the risk of antibody-dependent enhancement (ADE). Taken together, this review systematically summarizes recent global and regional trends in dengue fever and the current progress in dengue vaccine development, collectively offering a valuable resource for informing prevention and control strategies.
    • 加载中

      1. Ali, M., Pandey, R.K., Khatoon, N., Narula, A., Mishra, A.,Prajapati, V.K., 2017. Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. Sci. Rep., 7, 9232.

      2. Anumanthan, G., Sahay, B.,Mergia, A., 2025. Current dengue virus vaccine developments and future directions. Viruses, 17, 212.

      3. Asediya, V.S., Anjaria, P.A., Mathakiya, R.A., Koringa, P.G., Nayak, J.B., Bisht, D., Fulmali, D., Patel, V.A.,Desai, D.N., 2024. Vaccine development using artificial intelligence and machine learning: a review. Int. J. Biol. Macromol., 282, 136643.

      4. Biohub. 2025. Arming Burkina Faso Scientists with New Skills to Fight Dengue and Other Infectious Diseases.https://www.czbiohub.org/life-science/arming-burkina-faso-scientists-with-new-skills-to-fight-dengue-and-other-infectious-diseases/(accessed 1 March 2025).

      5. Biswal, S., Reynales, H., Saez-Llorens, X., Lopez, P., Borja-Tabora, C., Kosalaraksa, P., Sirivichayakul, C., Watanaveeradej, V., Rivera, L., Espinoza, F., et al., 2019. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N. Engl. J. Med., 381, 2009-2019.

      6. Biswal, S., Borja-Tabora, C., Martinez Vargas, L., Velasquez, H., Theresa Alera, M., Sierra, V., Johana Rodriguez-Arenales, E., Yu, D., Wickramasinghe, V.P., Duarte Moreira, E., Jr., et al., 2020. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. Lancet, 395, 1423-1433.

      7. Capeding, M.R., Tran, N.H., Hadinegoro, S.R., Ismail, H.I., Chotpitayasunondh, T., Chua, M.N., Luong, C.Q., Rusmil, K., Wirawan, D.N., Nallusamy, R., et al., 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet, 384, 1358-1365.

      8. Cattarino, L., Rodriguez-Barraquer, I., Imai, N., Cummings, D.a.T.,Ferguson, N.M., 2020. Mapping global variation in dengue transmission intensity. Sci. Transl. Med., 12, eaax4144.

      9. Chen, L., Zhang, X., Guo, X., Peng, W., Zhu, Y., Wang, Z., Yu, X., Shi, H., Li, Y., Zhang, L., Wang, L., Wang, P.,Cheng, G., 2022. Neighboring mutation-mediated enhancement of dengue virus infectivity and spread. EMBO Rep., 23, e55671.

      10. Danko, JR, Kochel, T, Teneza-Mora, N, Luke, TC, Raviprakash, K, Sun, P, Simmons, M, Moon, JE, De La Barrera, R, Martinez, LJ, Thomas, SJ, Kenney, RT, Smith, L, Porter, KR, 2018 Mar. Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial. Am J Trop Med Hyg 98 (3), 849–856.

      11. Durbin, A.P., Kirkpatrick, B.D., Pierce, K.K., Carmolli, M.P., Tibery, C.M., Grier, P.L., Hynes, N., Opert, K., Jarvis, A.P., Sabundayo, B.P., et al., 2016. A 12-Month-Interval dosing study in adults indicates that a single dose of the national institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response. J. Infect. Dis., 214, 832-835.

      12. Durbin, A.P., Pierce, K.K., Kirkpatrick, B.D., Grier, P., Sabundayo, B.P., He, H., Sausser, M., Russell, A.F., Martin, J., Hyatt, D., Cook, M., Sachs, J.R., Lee, A.W., Wang, L., Coller, B.A.,Whitehead, S.S., 2020. Immunogenicity and safety of a tetravalent recombinant subunit dengue vaccine in adults previously vaccinated with a live attenuated tetravalent dengue vaccine: results of a Phase-I randomized clinical trial. Am. J. Trop. Med. Hyg., 103, 855-863.

      13. Elfatimi, E., Lekbach, Y., Prakash, S.,Benmohamed, L., 2025. Artificial intelligence and machine learning in the development of vaccines and immunotherapeutics-yesterday, today, and tomorrow. Front Artif Intell, 8, 1620572.

      14. European Centre for Disease Prevention and Control. 2024. Dengue Worldwide Overview. https://www.ecdc.europa.eu (accessed 15 March 2025).

      15. FDA, 2023. DENGVAXIA. https://www.fda.gov/vaccines-blood-biologics/dengvaxia/(accessed 15 March 2025).

      16. Freedman DO. 2023. A new dengue vaccine (tak-003) now who recommended in endemic areas; what about travellers? J. Trav. Med., 30.10.1093/jtm/taad132. Available: https://doi.org/10.1093/jtm/taad132.

      17. General TS, Army Dot.A Phase 1, Randomized, open-label, single- Center, Comparison of Heterologous prime- Boost Vaccination Schedules of Tetravalent Dengue Virus Purified Inactivated Vaccine (Piv) and Tetravalent Dengue Virus Live Attenuated Vaccine (Lav) in Healthy Adults in a Nonendemic Region.2019.Available: https://cdn.clinicaltrials.gov/large-docs/38/NCT03141138/Prot_000.pdf.

      18. George, S.L., Wong, M.A., Dube, T.J., Boroughs, K.L., Stovall, J.L., Luy, B.E., Haller, A.A., Osorio, J.E., Eggemeyer, L.M., Irby-Moore, S., Frey, S.E., Huang, C.Y.,Stinchcomb, D.T., 2015. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial. J. Infect. Dis., 212, 1032-1041.

      19. Guo,Zq, 2018. Review of factors influencing transmission risk of dengue fever. Pract. Prev. Med.,25,1407-1409 (in Chinese).

      20. Hadinegoro, S.R., Arredondo-Garcia, J.L., Capeding, M.R., Deseda, C., Chotpitayasunondh, T., Dietze, R., Muhammad Ismail, H.I., Reynales, H., Limkittikul, K., Rivera-Medina, D.M., et al., 2015. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med., 373, 1195-1206.

      21. Huang, C.Y., Kinney, R.M., Livengood, J.A., Bolling, B., Arguello, J.J., Luy, B.E., Silengo, S.J., Boroughs, K.L., Stovall, J.L., Kalanidhi, A.P., Brault, A.C., Osorio, J.E.,Stinchcomb, D.T., 2013. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Neglected Trop. Dis., 7, e2243.

      22. Kallas, E.G., Precioso, A.R., Palacios, R., Thome, B., Braga, P.E., Vanni, T., Campos, L.M.A., Ferrari, L., Mondini, G., Da Graca Salomao, M., et al., 2020. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet Infect. Dis., 20, 839-850.

      23. Kallas, E.G., Cintra, M.a.T., Moreira, J.A., Patino, E.G., Braga, P.E., Tenorio, J.C.V., Infante, V., Palacios, R., De Lacerda, M.V.G., Batista Pereira, D., et al., 2024. Live, attenuated, tetravalent Butantan-dengue vaccine in children and adults. N. Engl. J. Med., 390, 397-408.

      24. Kayesh, M.E.H., Khalil, I., Kohara, M.,Tsukiyama-Kohara, K., 2023. Increasing dengue burden and severe dengue risk in Bangladesh: an overview. Trop. Med. Infect. Dis., 8, 32.

      25. Kirkpatrick, B.D., Durbin, A.P., Pierce, K.K., Carmolli, M.P., Tibery, C.M., Grier, P.L., Hynes, N., Diehl, S.A., Elwood, D., Jarvis, A.P., et al., 2015. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J. Infect. Dis., 212, 702-710.

      26. Kraemer, M.U., Sinka, M.E., Duda, K.A., Mylne, A.Q., Shearer, F.M., Barker, C.M., Moore, C.G., Carvalho, R.G., Coelho, G.E., Van Bortel, W., et al., 2015. The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus. Elife, 4, e08347.

      27. Kretschmer, M., Collins, J., Dale, A.P., Garrett, B., Koski, L., Zabel, K., Staab, R.N., Turnbow, K., Nativio, J., Andrews, K., et al., 2023. Notes from the field: first evidence of locally acquired dengue virus infection - maricopa county, Arizona, November 2022. MMWR Morb. Mortal. Wkly. Rep., 72, 290-291.

      28. Kumari, M., Su, S.C., Lin, H.T., Ko, S.H., Lu, Y.F., Chen, K.C., Chen, W.Y., Wu, M.J.,Wu, H.C., 2025. Enhanced immunogenicity of an mRNA vaccine against dengue virus serotype 2 with modified key residue. Vaccine, 57, 127216.

      29. Li, Z.W., Huang, X.X., Tian, T.T., Li, A.Q., Du, S.S., He, G.X.,Li, J.D., 2024. Epidemiological Characteristics of Reported Dengue Fever Cases in China, 2019-2023. vol. 24, 925-930 (in Chinese).

      30. Lin, L., Lyke, K.E., Koren, M., Jarman, R.G., Eckels, K.H., Lepine, E., Mcarthur, M.A., Currier, J.R., Friberg, H., Moris, P., Keiser, P.B., De La Barrera, R., Vaughn, D.W., Paris, R.M., Thomas, S.J.,Schmidt, A.C., 2020. Safety and immunogenicity of an AS03(B)-Adjuvanted inactivated tetravalent dengue virus vaccine administered on varying schedules to healthy U.S. adults: a phase 1/2 randomized study. Am. J. Trop. Med. Hyg., 103, 132-141.

      31. Lin, L., Koren, M.A., Paolino, K.M., Eckels, K.H., De La Barrera, R., Friberg, H., Currier, J.R., Gromowski, G.D., Aronson, N.E., Keiser, P.B., Sklar, M.J., Sondergaard, E.L., Jasper, L.E., Endy, T.P., Jarman, R.G.,Thomas, S.J., 2021. Immunogenicity of a live-attenuated dengue vaccine using a heterologous prime-boost strategy in a phase 1 randomized clinical trial. J. Infect. Dis., 223, 1707-1716.

      32. Liu, Q.Y., 2020. Dengue fever in China: new epidemical trend, challenges and strategies for prevention and control. Chin. J. Vector Biol. Control, 31, 1-6 (in Chinese).

      33. Ma, Y., Li, M., Xie, L., Gao, N., Fan, D., Feng, K., Yao, Y., Zhou, Y., Sheng, Z., Zhou, H., Chen, H., & An, J., 2022. Seroepidemiologic study on convalescent sera from dengue fever patients in Jinghong, Yunnan. Virol. Sin., 37, 19-29.

      34. Manoff, SB, Sausser, M, Falk Russell, A, Martin, J, Radley, D, Hyatt, D, Roberts, CC, Lickliter, J, Krishnarajah, J, Bett, A, Dubey, S, Finn, T, Coller, BA, 2019. Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults. Hum Vaccin Immunother 15 (9), 2195–2204.

      35. Mao, X.H.,Zhang, Z.X., 2007. Current situation of the dengue fever in China. The Current Epidemiological Situation of Dengue Fever in China, 2, 385-388 (in Chinese).

      36. McArthur MA, Edelman R. 2015. A promising, single-dose, live attenuated tetravalent dengue vaccine candidate. J. Infect. Dis., 212: 681-683. Available: https://doi.org/10.1093/infdis/jiv086.

      37. Messina, J.P., Brady, O.J., Golding, N., Kraemer, M.U.G., Wint, G.R.W., Ray, S.E., Pigott, D.M., Shearer, F.M., Johnson, K., Earl, L., et al., 2019. The current and future global distribution and population at risk of dengue. Nat. Microbiol., 4, 1508-1515.

      38. Miauton, A, Audran, R, Besson, J, Maby-El Hajjami, H, Karlen, M, Warpelin-Decrausaz, L, Sene, L, Schaufelberger, S, Faivre, V, Faouzi, M, Hartley, MA, Spertini, F, Genton, B, 2024 Jan. Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study. EBioMedicine 99, 104922.

      39. Modak, A., Mishra, S.R., Awasthi, M., Sreedevi, S., Sobha, A., Aravind, A., Kuppusamy, K.,Sreekumar, E., 2023. Higher-temperature-adapted dengue virus serotype 2 strain exhibits enhanced virulence in AG129 mouse model. FASEB J., 37, e23062.

      40. Osorio, J.E., Velez, I.D., Thomson, C., Lopez, L., Jimenez, A., Haller, A.A., Silengo, S., Scott, J., Boroughs, K.L., Stovall, J.L., Luy, B.E., Arguello, J., Beatty, M.E., Santangelo, J., Gordon, G.S., Huang, C.Y.,Stinchcomb, D.T., 2014. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect. Dis., 14, 830-838.

      41. Pandey, B.D.,Costello, A., 2019. The dengue epidemic and climate change in Nepal. Lancet, 394, 2150-2151.

      42. Pollett, S., Melendrez, M.C., Maljkovic Berry, I., Duchene, S., Salje, H., Cummings, D.a.T.,Jarman, R.G., 2018. Understanding dengue virus evolution to support epidemic surveillance and counter-measure development. Infect. Genet. Evol., 62, 279-295.

      43. Rivera, L., Biswal, S., Saez-Llorens, X., Reynales, H., Lopez-Medina, E., Borja-Tabora, C., Bravo, L., Sirivichayakul, C., Kosalaraksa, P., Martinez Vargas, L., et al., 2022. Three-year efficacy and safety of Takeda's dengue vaccine candidate (TAK-003). Clin. Infect. Dis., 75, 107-117.

      44. Rupp, R., Luckasen, G.J., Kirstein, J.L., Osorio, J.E., Santangelo, J.D., Raanan, M., Smith, M.K., Wallace, D., Gordon, G.S.,Stinchcomb, D.T., 2015. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study. Vaccine, 33, 6351-6359.

      45. Sabchareon, A., Wallace, D., Sirivichayakul, C., Limkittikul, K., Chanthavanich, P., Suvannadabba, S., Jiwariyavej, V., Dulyachai, W., Pengsaa, K., Wartel, T.A., Moureau, A., Saville, M., Bouckenooghe, A., Viviani, S., Tornieporth, N.G.,Lang, J., 2012. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet, 380, 1559-1567.

      46. Saez-Llorens, X., Tricou, V., Yu, D., Rivera, L., Tuboi, S., Garbes, P., Borkowski, A.,Wallace, D., 2017. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study. Lancet Infect. Dis., 17, 615-625.

      47. Saez-Llorens, X., Tricou, V., Yu, D., Rivera, L., Jimeno, J., Villarreal, A.C., Dato, E., Mazara, S., Vargas, M., Brose, M., Rauscher, M., Tuboi, S., Borkowski, A.,Wallace, D., 2018. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. Lancet Infect. Dis., 18, 162-170.

      48. Sharma, H., Ilyas, A., Chowdhury, A., Poddar, N.K., Chaudhary, A.A., Shilbayeh, S.a.R., Ibrahim, A.A.,Khan, S., 2022. Does COVID-19 lockdowns have impacted on global dengue burden? A special focus to India. BMC Public Health, 22, 1402.

      49. Sridhar, S., Luedtke, A., Langevin, E., Zhu, M., Bonaparte, M., Machabert, T., Savarino, S., Zambrano, B., Moureau, A., Khromava, A., et al., 2018. Effect of dengue serostatus on dengue vaccine safety and efficacy. N. Engl. J. Med., 379, 327-340.

      50. Subarna, R.T.,Saiyan, Z.A., 2024. Understanding the unprecedented 2023 dengue outbreak in Bangladesh: a data-driven analysis. IJID Reg, 12, 100406.

      51. Takeda, 2023. Takeda Announces Voluntary Withdrawal of U.S. Biologics License Application (BLA) for Dengue Vaccine Candidate TAK-003. https://www.takeda.com/newsroom/statements/2023/takeda-announces-voluntary-withdrawal-of-US-biologics-license-application-for-dengue-vaccine-candidate-TAK-003/(accessed 1 March 2025).

      52. Thomas, S.J.,Yoon, I.K., 2019. A review of dengvaxia®: development to deployment. Hum. Vaccines Immunother., 15, 2295-2314.

      53. Togami, E., Chiew, M., Lowbridge, C., Biaukula, V., Bell, L., Yajima, A., Eshofonie, A., Saulo, D., Hien, D.T.H., Otsu, S., et al., 2023. Epidemiology of dengue reported in the World Health Organization's Western Pacific Region, 2013-2019. West. Pac. Surveill. Response J., 14, 1-16.

      54. Tricou, V., Saez-Llorens, X., Yu, D., Rivera, L., Jimeno, J., Villarreal, A.C., Dato, E., Saldana De Suman, O., Montenegro, N., Deantonio, R., Mazara, S., Vargas, M., Mendoza, D., Rauscher, M., Brose, M., Lefevre, I., Tuboi, S., Borkowski, A.,Wallace, D., 2020. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. Lancet, 395, 1434-1443.

      55. Tricou, V., Yu, D., Reynales, H., Biswal, S., Saez-Llorens, X., Sirivichayakul, C., Lopez, P., Borja-Tabora, C., Bravo, L., Kosalaraksa, P., et al., 2024. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Global Health, 12, e257-e270.

      56. Venkatesan, P., 2024. Global upsurge in dengue in 2024. Lancet Infect Dis 24, e620.

      57. Villar, L., Dayan, G.H., Arredondo-Garcia, J.L., Rivera, D.M., Cunha, R., Deseda, C., Reynales, H., Costa, M.S., Morales-Ramirez, J.O., Carrasquilla, G., et al., 2015. Efficacy of a tetravalent dengue vaccine in children in Latin America. N. Engl. J. Med., 372, 113-123.

      58. Walsh, M.R., Alam, M.S., Pierce, K.K., Carmolli, M., Alam, M., Dickson, D.M., Bak, D.M., Afreen, S., Nazib, F., Golam, K., Qadri, F., Diehl, S.A., Durbin, A.P., Whitehead, S.S., Haque, R.,Kirkpatrick, B.D., 2024. Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial. Lancet Infect. Dis., 24, 150-160.

      59. Whitehead, S.S., 2016. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYDTM vaccine? Expert Rev. Vaccines, 15, 509-517.

      60. WHO, 2019a. Dengue Vaccine: WHO Position Paper, September 2018 - Recommendations. https://www.who.int/publications/i/item/who-wer9335-457-476 (accessed 15 March 2025).

      61. WHO, 2019b. Ten Threats to Global Health in 2019. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 (accessed 15 March 2025).

      62. WHO, 2023a. Dengue - Global Situation. https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON498#:∼:text=From%202000%20to%202019%2C%20the%20World%20Health%20Organization,worldwide%20increasing%20from%20500%20000%20to%205.2%20million (accessed 15 March 2025).

      63. WHO, 2023b. Dengue and Severe Dengue. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue (accessed 15 March 2025).

      64. WHO, 2023c. reportDengue in the WHO African Region: Situation Report 01: 19 December 2023. https://www.afro.who.int/countries/burkina-faso/publication/dengue-who-african-region-situation-report-01-19-december-2023 (accessed 15 March 2025).

      65. WHO,2024. Vaccines and Immunization: Dengue [EB/OL]. https://www.who.int/news-room/questions-and-answers/item/dengue-vaccines (accessed 2 January 2025).

      66. WHO, 2025. Dengue. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue (accessed 15 September 2025).

      67. Wilder-Smith, A., 2024. The dengue-in-dhaka initiative: results from a phase 2 trial evaluating the TV005 tetravalent dengue vaccine in Bangladesh. Lancet Infect. Dis., 24, 112-113.

      68. Wilder-Smith, A., 2024. TAK-003 dengue vaccine as a new tool to mitigate dengue in countries with a high disease burden. Lancet Global Health, 12, e179-e180.

      69. Williams, M., Mayer, S.V., Johnson, W.L., Chen, R., Volkova, E., Vilcarromero, S., Widen, S.G., Wood, T.G., Suarez-Ognio, L., Long, K.C., Hanley, K.A., Morrison, A.C., Vasilakis, N.,Halsey, E.S., 2014. Lineage II of Southeast Asian/American DENV-2 is associated with a severe dengue outbreak in the Peruvian Amazon. Am. J. Trop. Med. Hyg., 91, 611-620.

      70. Wollner, C.J., Richner, M., Hassert, M.A., Pinto, A.K., Brien, J.D.,Richner, J.M., 2021. A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses. J. Virol., 95, e02482.-20.

      71. Wu, T., Wu, Z.,Li, Y.P., 2022. Dengue fever and dengue virus in the People'S Republic of China. Rev. Med. Virol., 32, e2245 (in Chinese).

      72. Yuan, R.B.,Wang, H.M., 2005. The research progress of dengue fever. Shanghai Prevent. Med., 17, 167-169 (in Chinese).

      73. Yue, Y., Liu, X., Xu, M., Ren, D.,Liu, Q., 2019. Epidemiological dynamics of dengue fever in mainland China, 2014-2018. Int. J. Infect. Dis., 86, 82-93 (in Chinese).

      74. Yue Y, Liu Q, Liu X, Zhao N, Yin W. 2022. Dengue fever in mainland China, 2005-2020: a descriptive analysis of dengue cases and aedes data. Int. J. Environ. Res. Publ. Health, 19, 3910 (in Chinese).

      75. Yue, Y.J., Liu, X.B., Guo, Y.H., Zhao, N., Ren, D.S.,Liu, Q.Y., 2023a. Spatio-Temporal Distribution and Environmental Factors of Dengue Fever in China, 2020-2022. vol. 13, 341-345 (in Chinese).

      76. Yue, Y.J., Liu, X.B.,Ren, D.S., 2023b. Epidemiological Characteristics of Dengue Fever in Chinese mainland,2005-2020. vol. 34, 761-766,818 (in Chinese).

      77. Yue Y, Lun X, Zhao C, Liu X, Zhao N, Guo Y, Song X, Lu L, Ren D. 2025. Dengue situation in Chinese mainland, 2023. BMC Public Health, 25: 2773.10.1186/s12889-025-24151-8 (in Chinese).

    • 加载中

    Figures(1)

    PDF

    Article Metrics

    Article views(4698) PDF downloads(37) Cited by()

    Related
    Proportional views

      Current status of dengue fever epidemics and vaccine development

        Corresponding author: Ziyang Sheng, shengzy@ccmu.edu.cn
        Corresponding author: Na Gao, gao_na@ccmu.edu.cn
      • Department of Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China
      • Received Date: 29 May 2025
      • Accepted Date: 16 January 2026
      Fund Project:  the National Natural Science Foundation of Beijing (7232002) to N.G.This work was supported by grants from the National Natural Science Foundation of China (NSFC) (32370163) and the Beijing Municipal Natural Science Foundation-Joint Fund for Clinical Medicine Innovation of the Capital (L2510023) to Z.Y.S.

      Abstract: Dengue fever, an acute mosquito-borne infectious disease caused by dengue virus (DENV), is primarily endemic in tropical and subtropical regions. In recent years, the global incidence of dengue has increased dramatically. Since 2023, widespread outbreaks have been reported across numerous countries in the Americas, Asia and Africa. According to the World Health Organization, more than 5 million dengue cases were reported globally in 2023, while the number surged to over 14 million cases with more than 10,000 deaths in 2024—marking the highest global burden ever recorded. A similar upward trend has been observed in China, which experienced its largest dengue outbreak in a decade in 2024, with Guangdong Province accounting for the majority of domestically reported cases. These epidemiological patterns highlight the rapid expansion of dengue transmission, driven by climate change, accelerated urbanization and increased human mobility. In this context, vaccine development has become a public health priority. To date, two vaccines—Dengvaxia and Qdenga—have been licensed for clinical use. Six other vaccine candidates are currently in clinical trials, among which the tetravalent live-attenuated vaccines TV003/TV005 are considered the most promising. Despite considerable advances in dengue vaccine research, significant challenges remain, including the need to elicit balanced immune responses against the four serotypes and to reduce the risk of antibody-dependent enhancement (ADE). Taken together, this review systematically summarizes recent global and regional trends in dengue fever and the current progress in dengue vaccine development, collectively offering a valuable resource for informing prevention and control strategies.

        HTML

      Figure (1)  Reference (77) Relative (20)

      目录

      This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE)

      鄂ICP备05001977号

         

      鄂公网安备 42010602003674号

      Copyright © 2019 Virologica Sinica. All rights reserved

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return